Trafermin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Trafermin
Accession Number
DB06244
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description
Not Available
Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • Recombinant human basic fibroblast growth factor
  • rhbFGF
  • Trafermin
External IDs
CAB-2001
International/Other Brands
Fiblast (Kaken Pharmaceuticals Co., Ltd.)
Categories
UNII
333OX80X87
CAS number
131094-16-1

Pharmacology

Indication

Investigated for use/treatment in coronary artery disease, peripheral vascular disease, periodontal disease, bone fractures, entero-related fistulae, and diabetic foot ulcers.

Pharmacodynamics
Not Available
Mechanism of action

Trafermin, or basic fibroblast growth factor 2 (bFGF) is a recombinant human growth factor used to stimulate angiogenesis and keratinization in wound healing. It stimulates migration of monocytes, neutrophils, macrophages, fibroblasts and also assists in creation of granulation tissue (the tissue that replaces fibrin clots in healing wounds).

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
  1. Yamaguchi S, Asao T, Nakamura J, Tsuboi K, Tsutsumi S, Kuwano H: Effect of basic fibroblast growth factor, trafermin, on entero-related fistulae, report of two cases. Hepatogastroenterology. 2007 Apr-May;54(75):803-5. [PubMed:17591067]
  2. Bogousslavsky J, Victor SJ, Salinas EO, Pallay A, Donnan GA, Fieschi C, Kaste M, Orgogozo JM, Chamorro A, Desmet A: Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial. Cerebrovasc Dis. 2002;14(3-4):239-51. [PubMed:12403958]
External Links
Wikipedia
FGF2

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentPeriodontitis2
3CompletedTreatmentAlveolar Bone Losses / Periodontal Attachment Loss / Periodontitis1
3CompletedTreatmentPeriodontitis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on March 19, 2008 10:19 / Updated on June 04, 2019 06:22